​

Tonix Pharmaceuticals (TNXP) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

TNXP Stock Rating

Tonix Pharmaceuticals stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

TNXP Price Target Upside V Benchmarks

TypeNameUpside
StockTonix Pharmaceuticals-
SectorHealthcare Stocks 25.19%
IndustryBiotech Stocks 61.26%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$10.00$10.00$10.00
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25-2---2
Jan, 25-2---2
Dec, 24-2---2
Nov, 24-3---3
Oct, 24-3---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 22, 2024Alliance Global PartnersBuyBuyhold
Apr 11, 2024Noble Capital MarketsOutperformOutperformhold
Jun 02, 2022Noble FinancialBuyBuyhold
May 23, 2022Craig-HallumHolddowngrade

Financial Forecast

EPS Forecast

$-300 $-220 $-140 $-60 $20 $100 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.01-----
Avg Forecast$-267.84$-1.14$-0.62$-0.27$38.72$2.41
High Forecast$-254.72$-0.07$-0.04$-0.09$55.01$3.42
Low Forecast$-281.60$-2.19$-1.20$-0.45$19.80$1.23
Surprise %-100.00%-----

Revenue Forecast

$0 $180M $360M $540M $720M $900M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.77M-----
Avg Forecast$10.33M$12.80M$13.35M$30.60M$379.69M$657.95M
High Forecast$10.40M$13.79M$18.14M$40.50M$502.57M$870.88M
Low Forecast$10.26M$11.81M$8.55M$19.10M$236.94M$410.59M
Surprise %-24.83%-----

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-116.66M-----
Avg Forecast$-142.79M$-604.19K$-329.83K$-143.77K$20.62M$1.28M
High Forecast$-135.63M$-39.77K$-22.54K$-47.92K$29.29M$1.82M
Low Forecast$-149.95M$-1.17M$-637.13K$-239.62K$10.54M$656.08K
Surprise %-18.30%-----

TNXP Forecast FAQ

Is Tonix Pharmaceuticals stock a buy?

Tonix Pharmaceuticals stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Tonix Pharmaceuticals is a favorable investment for most analysts.

What is Tonix Pharmaceuticals's price target?

Tonix Pharmaceuticals's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $10.

How does Tonix Pharmaceuticals stock forecast compare to its benchmarks?

Tonix Pharmaceuticals's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (25.19%) and underperforming the biotech stocks industry (61.26%).

What is the breakdown of analyst ratings for Tonix Pharmaceuticals over the past three months?

  • February 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Tonix Pharmaceuticals’s EPS forecast?

Tonix Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2024 is $-1.14, marking a 11300.00% increase from the reported $-0.01 in 2023. Estimates for the following years are $-0.62 in 2025, $-0.27 in 2026, $38.72 in 2027, and $2.41 in 2028.

What is Tonix Pharmaceuticals’s revenue forecast?

Tonix Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2024 is $12.8M, reflecting a 64.78% increase from the reported $7.77M in 2023. The forecast for 2025 is $13.35M, followed by $30.6M for 2026, $379.69M for 2027, and $657.95M for 2028.

What is Tonix Pharmaceuticals’s net income forecast?

Tonix Pharmaceuticals's net income forecast for the fiscal year ending in December 2024 stands at $-604K, representing a -99.48% decrease from the reported $-117M in 2023. Projections indicate $-330K in 2025, $-144K in 2026, $20.62M in 2027, and $1.28M in 2028.